Park Square has placed Ingo Chakravarty as Operating Partner at Northpond Ventures. Northpond Ventures builds and supports breakthrough science and technology driven businesses to create a marked impact on humanity.

Chakravarty most recently served as Vice President and General Manager at Thermo Fisher. He held this role from 2021-2023. He was formerly the President and Chief Executive Officer at Mesa Biotech, a private developer of DNA and RNA molecular testing services, from 2020-2021. Mesa Biotech was acquired by Thermo Fisher Scientific in 2021 for $450 million. From 2016-2019, he served as President and Chief Executive Officer at NAVICAN, a private provider of a comprehensive end-to-end solution to help oncologists and patients. Prior, he was Senior Vice President and General Manager, International from 2013-2016 at GenMark Diagnostics, a public molecular diagnostics company developing sensor detection technology. GenMark Diagnostics was acquired by Roche in 2021 for $1.8 billion. From 2011-2012, Chakravarty was Vice President and General Manager, Women’s Health at Gen-Probe, a private developer of nucleic acid probe-based products for clinical diagnosis. Previously, he served as Head, Sales, Europe at Roche Tissue Diagnostics from 2009-2011. Chakravarty held a variety of leadership roles at Ventana Medical Systems from 2004-2008 and joined the company as Sales Manager in Germany and France from 1996-2003. He began his career as Sales Manager at Microm Laborgeraete from 1990-1996 in Germany.

Chakravarty received his B.S. in Electrical Engineering from Friedrich Hecker School.